CanadaBuys #BCPHSA_-_19193

Providence Health Care seeks Abbott DRG therapy for chronic pain management

Providence Health Care is seeking targeted Dorsal Root Ganglion (DRG) therapy for patients with chronic pain that may not respond to traditional spinal cord stimulation. - Government buyer: Providence Health Care; no sub-agency or purchasing office is specified. - OEM: Abbott Medical Canada is identified as the only supplier and manufacturer in Canada of a Health Canada-approved DRG therapy platform. - Requested solution: DRG therapy for complex regional pain syndrome and other focal neuropathic pain conditions. The notice highlights targeted stimulation, reduced positional variability, and programming tailored to individual patient needs. - Products and quantities: No model, part number, or purchase quantity is provided. No separate services or priced line items are identified. - Notable requirement: The requested therapy is intended for chronic pain conditions not effectively managed with traditional spinal cord stimulation. - Performance period and value: Not specified in the available notice.

Description

The solicitation concerns Dorsal Root Ganglion (DRG) therapy for chronic conditions including complex regional pain syndrome and other focal neuropathic pain syndromes not effectively managed with traditional spinal cord stimulation. DRG provides targeted stimulation and enhanced programming capabilities to tailor treatment to individual patient needs. The source states Abbott Medical Canada is currently the only supplier and manufacturer of a Health Canada-approved DRG therapy platform in Canada. Full tender details are available through a third-party site.

View original listing